Creative Biolabs, a biotechnology and life sciences company, is enhancing its integrated immuno-oncology suite, bridging the gap between advanced diagnostics and therapeutic discovery. By synthesizing tumor molecular profiling, gut microbiota analysis, and high-affinity antibody engineering, the company provides a cohesive ecosystem designed to accelerate personalized cancer treatment.
Explore how integrated multi-omics can support your research program; visit Creative Biolabs’ immuno-oncology services (tumor profiling & antibody discovery solutions).
Advancing Precision Medicine via Multiscale Tumor Profiling
As oncology shifts toward personalized intervention, the need for comprehensive molecular insights has become paramount. Creative Biolabs addresses this through a multiscale profiling laboratory that utilizes Next-Generation Sequencing (NGS), In Situ Hybridization (ISH), and Immunohistochemistry (IHC) to characterize the unique biological landscape of solid tumors and liquid biopsies.
“Precision medicine is no longer a future concept; it is the current standard,” says a senior scientist at Creative Biolabs. “Our comprehensive tumor analysis services allow researchers to decode DNA, RNA, and protein biomarkers across diverse cancers—from non-small cell lung cancer to metastatic melanoma—ensuring that every therapeutic decision is backed by high-quality molecular data.”
The Microbiome Frontier: A New Dimension in Diagnostics
A distinguishing feature of Creative Biolabs’ recent expansion is its focus on the “Brain-Immune-Gut” axis. Emerging research indicates that the human microbiome significantly influences immunotherapy efficacy. The company’s gut microbiota-based diagnostics platform utilizes metagenomic and metabolomic analyses to identify microbial signatures that correlate with clinical outcomes. This technology enables the identification of early biomarkers for complications like stroke-related brain injury or post-operative cancer recurrence.
Interested in microbiome-based biomarker discovery? Contact Creative Biolabs for gut microbiome analysis solutions.
This technology enables the identification of early biomarkers for complications like stroke-related brain injury or post-operative cancer recurrence.
Streamlining Therapeutic Discovery and Engineering
Beyond diagnostics, Creative Biolabs maintains a robust antibody and protein discovery engine. Leveraging proprietary phage display and hybridoma platforms, the company facilitates the development of complex modalities, including:
- Bispecific Antibodies (BsAbs): Enhancing immune response by targeting dual antigens.
- Antibody-Drug Conjugates (ADCs): Delivering cytotoxic payloads with surgical precision.
By integrating target validation with advanced antibody engineering—such as humanization and affinity maturation—the company reduces development timelines from years to weeks.
Integrated Precision Oncology Workflow
To translate discovery capabilities into clinically actionable outcomes, Creative Biolabs integrates these technologies into a structured precision oncology workflow.
Step 1: Tumor & Microbiome Profiling
- · NGS + metagenomics data collection
Step 2: Biomarker Identification
- · Integration of genomic + microbial + protein signals
Step 3: Target Validation
- · Functional validation in immune context
Step 4: Therapeutic Engineering
- · Antibody design (BsAbs, ADCs)
Step 5: Optimization
- · Affinity maturation and humanization
Addressing Complexity in Immuno-Oncology
To support global researchers, Creative Biolabs has integrated technical insights addressing common industry challenges:
- How does multi-omics integration improve trial success? By correlating bacterial composition with host gene expression, researchers can de-risk pipelines before clinical milestones.
- Can these services be customized for rare cancers? Yes, the platforms are modality-agnostic and can be tailored for unique tumor microenvironments, including hypoxic or treatment-resistant tissues.
Commitment to Quality and Global Collaboration
Creative Biolabs continues to set the benchmark for quality, operating under ISO 9001 certified management systems. With a team of tenured scientists and 24/7 responsiveness, the company serves as a strategic partner for pharmaceutical and academic institutions worldwide.
